| # | Drug | Count |
|---|---|---|
| 0 | LETROZOLE | 47 |
| 1 | LETROZOLE TABLETS | 42 |
| 2 | RIBOCICLIB | 40 |
| 3 | FULVESTRANT | 30 |
| 4 | METHOTREXATE SODIUM | 29 |
| 5 | ETANERCEPT | 27 |
| 6 | METHOTREXATE | 25 |
| 7 | LEVONORGESTREL | 20 |
| 8 | ADALIMUMAB | 19 |
| 9 | PANTOPRAZOLE | 19 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | VADADUSTAT | 1 | 0.0033 |
| 1 | CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE | 1 | 0.0023 |
| 2 | TOCILIZUMAB-AAZG | 1 | 0.0016 |
| 3 | GOSERELIN | 17 | 0.0013 |
| 4 | RIBOCICLIB | 40 | 0.0012 |
| 5 | DARIFENACIN HYDROBROMIDE | 1 | 0.0012 |
| 6 | DEXRAZOXANE FOR INJECTION | 1 | 0.0011 |
| 7 | FULVESTRANT | 30 | 0.0009 |
| 8 | LETROZOLE TABLETS | 42 | 0.0009 |
| 9 | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 4 | 0.0008 |
| # | Drug class | Count |
|---|---|---|
| 0 | Aromatase Inhibitor [EPC] | 60 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 35 |
| 2 | Corticosteroid [EPC] | 30 |
| 3 | Estrogen Receptor Antagonist [EPC] | 30 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 25 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 24 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 24 |
| 7 | Progestin [EPC] | 23 |
| 8 | Microtubule Inhibitor [EPC] | 20 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 20 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Endoglycosidase [EPC] | 4 | 0.0022 |
| 1 | Estrogen Receptor Antagonist [EPC] | 30 | 0.0007 |
| 2 | Aromatase Inhibitor [EPC] | 60 | 0.0005 |
| 3 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | 1 | 0.0004 |
| 4 | Provitamin D2 Compound [EPC] | 13 | 0.0004 |
| 5 | Sulfonamide Antibacterial [EPC] | 1 | 0.0003 |
| 6 | Interleukin-17A Antagonist [EPC] | 8 | 0.0002 |
| 7 | HER2/neu Receptor Antagonist [EPC] | 15 | 0.0002 |
| 8 | Integrin Receptor Antagonist [EPC] | 16 | 0.0002 |
| 9 | CD38-directed Cytolytic Antibody [EPC] | 1 | 0.0002 |